{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444541801
| IUPAC_name = (±)-4,4'-<nowiki/>{Hexane-1,6-diyl''bis''[imino(1-hydroxyethane-2,1-diyl)]}dibenzene-1,2-diol
| image = Hexoprenaline.svg
| width = 225px
| chirality = [[Racemic mixture]]

<!--Clinical data-->
|pronounce={{IPAc-en|ˌ|h|ɛ|k|s|oʊ|ˈ|p|r|ɛ|n|ə|l|iː|n}} {{respell|HEKS|oh|PREN|ə|leen}}
| tradename =  
| Drugs.com = {{drugs.com|international|hexoprenaline}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = ℞-only
| routes_of_administration = Oral ([[Tablet (pharmacy)|tablets]]), [[Intravenous therapy|IV]]

<!--Pharmacokinetic data-->
| bioavailability = 5–11% ([[Cmax (pharmacology)|T<sub>max</sub>]] = 2 hours)
| protein_bound =  
| metabolism = [[Catechol-O-methyl transferase|COMT]] (slow ''O''-methylation)
| elimination_half-life = ~50 minutes (if taken orally)
| excretion = Feces (~90%)<ref name="PI">{{cite web|title=Gynipral (hexoprenaline) Full Prescribing Information|url=http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=143837&t=|website=Russian State Register of Medicinal Products|publisher=Nycomed Austria GmbH. St. Peter-Straße 25, A-4020, Linz, Austria|accessdate=19 March 2016|language=Russian}}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3215-70-1
| ATC_prefix = R03
| ATC_suffix = AC06
| ATC_supplemental = {{ATC|R03|CC05}}
| PubChem = 3609
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB08957
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08039
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G9L6B3W684
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 3483

<!--Chemical data-->
| chemical_formula =  
| C = 22 | H = 32 | N = 2 | O = 6 
| molecular_weight = 420.499 g/mol
| smiles = C1=CC(=C(C=C1C(CNCCCCCCNCC(C2=CC(=C(C=C2)O)O)O)O)O)O
| synonyms = <small>4-[2-[6-<nowiki>[[</nowiki>2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol</small>
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H32N2O6/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16/h5-8,11-12,21-30H,1-4,9-10,13-14H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = OXLZNBCNGJWPRV-UHFFFAOYSA-N
}}

'''Hexoprenaline''' is a selective [[Beta2-adrenergic agonist|β<sub>2</sub> adrenergic receptor]] [[agonist]] used in the treatment of [[asthma]].<ref>{{cite journal|last1=Pinder|first1=RM|last2=Brogden|first2=RN|last3=Speight|first3=™|last4=Avery|first4=GS|title=Hexoprenaline|journal=Drugs|date=July 1977|volume=14|issue=1|pages=1–28|doi=10.2165/00003495-197714010-00001|pmid=195789}}<!--|accessdate=19 March 2016--></ref> Hexoprenaline is also used in some countries (such as [[Russia]] and [[Switzerland]]) as a [[tocolytic]] agent (i.e., labor suppressant), with the most common trade name being '''Gynipral'''.<ref name = "RLS">{{cite web|title=Gynipral (hexoprenaline) Tablets 0.5 mg, Solution for Intravenous Infusion 5 ''μ''g/mL (0.0005%)|url=http://www.rlsnet.ru/tn_index_id_1005.htm|website="RLS" (РЛС): Russian Register of Medical Products|language=Russian|accessdate=19 March 2016}}</ref> <ref name="Compendium">{{cite web|title=GYNIPRAL Inj Lös 10 mcg/2ml|url=https://compendium.ch/prod/gynipral-inj-los-10-mcg-2ml/de|website="Compendium": Swiss Register of Medical Products|language=German|accessdate=3 April 2017}}</ref> It is not approved by U.S. [[Food and Drug Administration|FDA]].

==Contraindications==
When used as a tocolytic, hexoprenaline is contraindicated in:
* [[Hyperthyroidism]]
* [[Cardiovascular disease]]s, e.g. cardiac [[arrhythmia]]s, [[tachycardia]], [[myocarditis]], [[Mitral insufficiency|mitral valve disease]] and [[aortic stenosis]]
* [[Coronary artery disease|Ischemic heart disease]]
* [[Hypertension]]
* Angle-closure [[glaucoma]]
* [[Placental abruption]], [[vaginal bleeding]] and inflammatory diseases of internal genitalia (such as [[endometritis]])
* [[Shock (circulatory)|Shock]]
* First trimester of [[pregnancy]]
* [[Breastfeeding]]<ref name="PI" /><ref name = "RLS" />

It should be used with caution in people with [[gestational diabetes]].

==Drug-drug interactions==
When concomitantly administered:
* [[Beta blockers]] reduce or neutralize therapeutic effects of hexoprenaline
* [[Xanthine|Methylxanthines]] ([[caffeine]], [[theobromine]], [[theophylline]]) increase its action
* [[General anaesthetic]]s (e.g., [[halothane]]) and [[Adrenergic agonist|adrenergic receptor agonists]] may increase the risk of cardiovascular side effects, such as arrhythmia

Hexoprenaline is contraindicated for use with [[Monoamine oxidase inhibitor|monoamine oxidase inhibitors (MAOIs)]], [[Tricyclic antidepressant|tricyclic antidepressant (TCAs)]], [[ergot]] alkaloids, and [[dihydrotachysterol]].<ref name = "RLS" />

==References==
<references/>

{{Other gynecologicals}}
{{Drugs for obstructive airway diseases}}
{{Adrenergics}}

[[Category:Antiasthmatic drugs]]
[[Category:Beta-adrenergic agonists]]
[[Category:Catecholamines]]
[[Category:Tocolytics]]

{{respiratory-system-drug-stub}}